SYRE – spyre therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears [Yahoo! Finance]
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.
Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio [Yahoo! Finance]
Form ARS Spyre Therapeutics, Inc. For: Dec 31
Form DEFA14A Spyre Therapeutics, Inc.
Form DEF 14A Spyre Therapeutics, Inc. For: May 27
Form 4 Spyre Therapeutics, Inc. For: Apr 01 Filed by: Turtle Cameron
Form 4 Spyre Therapeutics, Inc. For: Apr 01 Filed by: Sloan Sheldon
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.